Answer extracted from the B2B Vault: The Biz To Biz Podcast — listen to the full episode below.
What enforcement actions have occurred against research-only peptide sellers?
Research-only peptide companies have faced fines ranging from $50,000 to $200,000, with enforcement escalating dramatically in some cases. One company paid over $70 million in a settlement with pharmaceutical companies and faced up to seven years in jail, with employees also required to pay back money.
The Scale of Enforcement Against Illegal Peptide Operations
The penalties vary based on the severity of violations, but the baseline enforcement sends a clear message: operating illegally in the research peptide space carries serious financial consequences. As Angela Salter explains on the podcast, companies operating outside the regulatory framework face immediate FTC and FDA intervention.
The most severe case documented involved a research-only peptide company that not only paid millions in civil penalties but also faced criminal charges resulting in jail sentences for executives. This reflects a coordinated enforcement effort between federal agencies and pharmaceutical companies protecting their intellectual property and market interests.
"We certify based on current applicable laws and regulations, not what a committee thinks might be true in a year or two."
Angela Salter — Vice President of Enterprise Certification Sales and Partnerships at LegitScript. Angela oversees enterprise customers and account management for certification clients, as well as strategic partnerships with payment processors and advertising platforms like Visa and MasterCard that require LegitScript certification for telemedicine and pharmacy merchants.
Beyond direct fines, companies found violating regulations are placed on match lists maintained by federal authorities, card brands, and ad platforms. These match lists remain active for five years, effectively blacklisting companies from legitimate payment processing and advertising channels.
The enforcement also extends to individual employees: executives and operators can face personal liability, including jail time and mandatory repayment obligations. This personal accountability has proven effective in deterring new entrants into the illegal peptide market. The podcast also covers how major pharmaceutical companies like Eli Lilly have filed reports on thousands of websites, triggering multi-agency investigations.
Key takeaways
- Fines for illegal research peptide operations range from $50,000 to $200,000 for standard violations.
- At least one company faced a $70 million+ civil settlement with pharmaceutical companies plus criminal jail time for executives.
- Convicted operators face up to seven years imprisonment and mandatory repayment obligations.
- Violating companies are placed on federal match lists for five years, barring access to payment processors and ad platforms.
See also
How did compounding pharmacies need to adapt after the GLP-1 shortage ended?
When the FDA shortage was deemed over, the FDA announced a specific timeframe for compounding pharmacies to cease GLP-1 operations. LegitScript helped merchants achieve a 100 percent compliance rate when transitioning out of GLP-1 compounding.
What is the current legal status of peptide compounds like BCP157 and TB500 for compounding and sale?
As of now, nothing has legally changed from a legal standpoint. The FDA's advisory committee signaled that these peptides might eventually have a legitimate pathway, but LegitScript certifies based on current applicable laws and regulations.
Why do payment processors and advertising platforms require LegitScript certification?
Payment processors and advertising platforms like Visa, MasterCard, Google, and Meta require certification to align with their policies and reduce the risk of fake, dangerous, or misleading healthcare advertising.